The GSK share price: Is now the time to buy?

GlaxoSmithKline plc (LON: GSK) smashed through forecasts with its Q1 figures. But investors shouldn’t get carried away, says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The latest quarterly figures from pharma giant GlaxoSmithKline (LSE: GSK) slipped under the radar for many investors on Wednesday, but I think they showed encouraging signs of growth.

Today I want to look at the good (and bad) news from the FTSE 100 firm’s first-quarter numbers, and give my view on the shares. I’ll also take a look a smaller dividend stock with a tempting 6%+ yield.

Ahead of expectations

A new two-part HIV treatment and the shingles vaccine Shingrix helped Glaxo deliver sales and profits that were comfortably ahead of analysts’ forecasts during the quarter.

The group’s sales rose by 5% to £7.7bn, compared to forecasts of £7.5bn. Adjusted earnings climbed 18% to 30.1p per share, comfortably ahead of forecasts of 26.1p.

Several new respiratory products also delivered strong growth, with sales rising by 25% to £631m. However, this gain carries a sting in the tail, as I’ll explain.

Cheap copy drugs pose threat

Glaxo warned that despite its strong first-quarter performance, expectations for a 5%-9% fall in adjusted earnings this year are unchanged.

Why? One of the firm’s most successful medicines, asthma drug Advair, is likely to start losing sales to a much cheaper generic alternative, which was recently approved by the US authorities.

Forecasts for the full year are also dependent on the firm’s consumer healthcare deal with Pfizer completing by the end of the year. As I’ve explained before, I think this deal should eventually help to secure Glaxo’s dividend and reduce its debt load.

For now, the firm expects to maintain the dividend payout at 80p per share, giving Glaxo stock a forecast dividend yield of 5.1%. Although this payout looks stretched to me, I still think these shares are likely to be a good long-term buy for income investors.

Should you buy this 6.6% yield?

Insurance firm Lancashire Holdings (LSE: LRE) is a long-time favourite of mine. This specialist business provides insurance for large valuable assets such as oil rigs, ships and airliners.

The firm’s shares offer a tempting forecast dividend yield of 6.6% for 2019, but despite a solid trading update today, I’m not sure that now is the time to rush into this stock.

That might seem a strange view, given the insurer’s attractive dividend yield. However, the firm’s payout is largely dependent on a special dividend the firm pays each year based on how much surplus capital it has.

Various factors influence this payout, including the cost of major claims and how many new business opportunities the company has. At this early stage in the year, it’s hard to say whether current forecasts will prove accurate. However, last year’s dividend payout of $0.35 per share was significantly below forecasts in October for $0.44 per share.

Although analysts have pencilled in a payout of $0.59 per share for 2019, there’s no guarantee this will be possible.

Chief executive Alex Maloney says that the firm is seeing early evidence of a return to stronger pricing. But premiums written by it only rose by 0.6% to $217.2m during the first quarter, suggesting any improvement in pricing power is limited.

Lancashire stock now trades at nearly 14 times 2019 forecast earnings and at 1.6 times its book value. In my view that’s probably high enough. I rate Lancashire as a long-term income stock. But I’d wait for the shares to dip before buying. I’d hold.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »